Glofitamab for Relapsed or Refractory Diffuse Large B-Cell LymphomaMichael Dickinson, Martin Hutchings, Cyrus Khan et al.|New England Journal of Medicine|2022Cited by 718
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I TrialMartin Hutchings, Michael Dickinson, Franck Morschhauser et al.|Journal of Clinical Oncology|2021Cited by 428
Glofitamab Step-up Dosing Induces High Response Rates in Patients with Hard-to-Treat Refractory or Relapsed Non-Hodgkin LymphomaMartin Hutchings, Michael Dickinson, Carmelo Carlo‐Stella et al.|Blood|2020Cited by 56